NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications
The Company requires additional time to activate clinical sites in certain countries that are participating in its long-term safety trial (trial 012, the “BeyoND” trial) of ND0612> Read More
NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting
Data Presented at 4th World Parkinson Congress > Read More
NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
The data will be presented at the 4th World Parkinson Congress (WPC) taking place in Portland, Oregon, on September 20-23.”> Read More